Introduced September 18, 2025 by Robert F. Onder · Last progress September 18, 2025
The bill aims to protect children from irreversible gender‑affirming medical interventions and to provide federal civil remedies for survivors, but it substantially increases legal exposure for providers, risks reducing timely access to evidence‑based care (especially for minors and rural patients), and may raise costs and administrative burdens for the health system.
Children and minors are barred from receiving puberty blockers, cross‑sex hormones, or sex‑changing surgeries, reducing the risk of irreversible medical interventions on youth.
The bill preserves medically necessary exceptions (e.g., verified disorders of sexual development and emergent organ‑system conditions) and explicitly allows detransition care, reducing the risk that urgent intersex care or corrective care will be denied.
Survivors and their parents/guardians can bring federal civil claims for prohibited procedures, seek compensatory and non‑economic damages (and punitive damages in cases of malicious/reckless conduct), and have extended time windows to file certain claims.
Minors with gender dysphoria may lose access to evidence‑based, clinician‑recommended gender‑affirming treatments, increasing the risk of psychological distress, worsening mental‑health outcomes, and potential self‑harm for affected youth.
Providers face substantial criminal, civil, and professional exposure (including strict liability and unclear definitional standards), creating a chilling effect that could drive clinicians and clinics to refuse or limit care for transgender and gender‑diverse patients.
Insurers and state health programs may be required or induced to deny coverage for gender‑affirming treatments for minors, shifting costs to families, increasing out‑of‑pocket burdens, and potentially increasing emergency or crisis care later.
Based on analysis of 7 sections of legislative text.
Prohibits puberty blockers, cross‑sex hormones, and sex‑altering surgeries for people under 18 under federal jurisdiction and creates a retroactive federal private right of action permitting damages.
Prohibits health care professionals, hospitals, and clinics from providing puberty blockers, cross‑sex hormones, or sex‑altering surgeries to anyone under 18 under circumstances that bring the conduct under federal jurisdiction (for example, interstate travel, telemedicine, or use of interstate commerce). The bill defines those interventions as “chemical or surgical mutilation,” narrows narrow medical exceptions, requires providers to prove exceptions by clear and convincing evidence, creates a federal private right of action (retroactive) allowing victims or their parents/guardians to sue for compensatory, non‑economic, and punitive damages, and sets a long statute of limitations (until age 43 or four years after detransition costs, whichever is later).